Clinical Presentation & Protocol
Patient Usually Complains Of
Patient presents with clinical features suggestive of C3 glomerulopathy, specifically Dense Deposit Disease (DDD). History significant for [hematuria/proteinuria/nephrotic syndrome]. Evaluation for alternative complement pathway dysregulation is ongoing. Review of systems positive for [edema/fatigue/hypertension]. Note presence or absence of acquired partial lipodystrophy (Barraquer-Simons syndrome).
Clinical Examination Findings
General appearance: [Stable/Ill-appearing]. Vital signs: BP [Value], HR [Value]. Physical exam reveals [pitting edema/anasarca]. Skin assessment: Check for signs of partial lipodystrophy, specifically loss of subcutaneous fat in the face, neck, and upper trunk.
Treatment Protocol
Management plan includes: 1. Strict blood pressure control (target <120/80 mmHg) using ACE inhibitors or ARBs. 2. Immunosuppressive therapy as indicated (e.g., mycophenolate mofetil, corticosteroids). 3. Consideration of complement-targeted therapy (e.g., eculizumab) in refractory cases. 4. Monitoring of C3 levels and renal function (eGFR, UPC ratio).